BioMarin Pharmaceutical, Inc. (BMRN)
62.92
-1.16
(-1.81%)
USD |
NASDAQ |
Feb 23, 16:00
61.43
-1.49
(-2.37%)
Pre-Market: 08:14
BioMarin Pharmaceutical Research and Development Expense (Quarterly) : 188.52M for Sept. 30, 2025
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Amicus Therapeutics, Inc. | 23.74M |
| Gilead Sciences, Inc. | 1.565B |
| Merck & Co., Inc. | 3.992B |
| AbbVie, Inc. | 2.579B |
| Bristol Myers Squibb Co. | 2.561B |